

NEUROCRINE BIOSCIENCES INC

Form 4

June 24, 2013

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Grigoriadis Dimitri E.

(Last) (First) (Middle)

NEUROCRINE BIOSCIENCES,
INC., 12780 EL CAMINO REAL

(Street)

SAN DIEGO, CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
SymbolNEUROCRINE BIOSCIENCES
INC [NBIX]3. Date of Earliest Transaction
(Month/Day/Year)

06/20/2013

4. If Amendment, Date Original
Filed(Month/Day/Year)5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
☒ Officer (give title below) ____ Other (specify below)

Chief Research Officer

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
 ____ Form filed by More than One Reporting
 Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2013		S ⁽²⁾		900	D	\$ 12.54 (3)
Common Stock	06/20/2013		S ⁽²⁾		20,000	D	\$ 12.29 (4)
Common Stock	06/21/2013		S ⁽²⁾		20,000	D	\$ 12.69 (5)
Common	06/21/2013		S ⁽²⁾		4,100	D	\$ 12.5 75,433

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

Stock					(6)		
Common Stock	06/21/2013	S(2)	900	D	\$ 13 (7)	75,433	D
Common Stock	06/21/2013	S(2)	937	D	\$ 13	75,433	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Security (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nonstatutory Stock Option	\$ 2.59	06/20/2013		X ⁽¹⁾		20,000		10/11/2010	05/11/2017	Common Stock	20,000
Nonstatutory Stock Option	\$ 2.59	06/21/2013		X ⁽¹⁾		20,000		10/11/2010	05/11/2017	Common Stock	20,000
Incentive Stock Option	\$ 5.12	06/20/2013		X ⁽¹⁾		900		02/27/2008	02/27/2015	Common Stock	900
Incentive Stock Option	\$ 5.12	06/21/2013		X ⁽¹⁾		4,100		02/27/2008	02/27/2015	Common Stock	4,100
Nonstatutory Stock Option	\$ 10.9	06/21/2013		X ⁽¹⁾		937		09/26/2007	07/23/2013	Common Stock	937
Nonstatutory Stock Option	\$ 10.9	06/21/2013		X ⁽¹⁾		900		09/26/2007	09/26/2013	Common Stock	900

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Grigoriadis Dimitri E. NEUROCRINE BIOSCIENCES, INC.	Chief Research Officer

12780 EL CAMINO REAL
SAN DIEGO, CA 92130

Signatures

Margaret E. Valeur-Jensen, By Power of
Attorney

06/24/2013

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Exercise of in-the-money or at-the money derivative security

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

(3) Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.51-\$12.71, inclusive. The

(4) Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.12-\$12.51, inclusive. The

(5) Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.50-\$12.92, inclusive. The

(6) Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.50-\$12.53, inclusive. The

(7) Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.00-\$13.01, inclusive. The

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.